You are here: Industry Insights > AbbVie

News List

VENCLEXTA, Low-Dose Cytarabine Combination Study for AML Does Not Meet Primary Endpoint americanpharmaceuticalreview
March 04, 2020
AbbVie announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA?) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of ...
Allergan to fork over a hefty $300M to wrap pay-for-delay suit fiercepharma
January 07, 2020
With AbbVie and Allergan almost ready to wrap up their $63 billion megamerger, both drugmakers are looking to clear any outstanding accounts before the deal closes. And Allergan just agreed to fork over $300 million to resolve one of them.
AbbVie Receives EC Approval of RINVOQ for Rheumatoid Arthritis americanpharmaceuticalreview
December 19, 2019
AbbVie announced the European Commission (EC) has approved RINVOQ? (upadacitinib) for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have ...
UCB Trial Achieves Endpoints ContractPharma
December 11, 2019
Phase III study met its co-primary and secondary endpoints demonstrating superiority of bimekizumab to Abbvie’s Humira in plaque psoriasis
AbbVie and Scripps Research form drug development alliance pharmaceutical-technology
December 11, 2019
AbbVie has teamed up with non-profit biomedical research and drug discovery organisation Scripps Research to create cancer, immunology, neurology and fibrosis treatments, among others.
BioMed X Completes Alzheimer’s Disease Research Project b3cnewswire
October 29, 2019
BioMed X announced the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease.
AbbVie's premium bid for Allergan isn't enough for one investor, who's suing to block it fiercepharma
September 26, 2019
AbbVie agreed to buy Allergan in June, offering $188 per share, or?a 45% premium to the company's shares at the time. It was a price and a deal that analysts assessed as a boon for Allergan shareholders.
FDA red-flags liver risks for AbbVie, Merck, Gilead hep C drugs fiercepharma
September 02, 2019
Next-gen hepatitis C meds typically cure the disease with minimal side effects. But the FDA says it's tracking rare cases of liver damage, liver failure and death in patients using some top-selling drugs—mostly patients who shouldn't have been using the d
AbbVie Discontinues Rova-T Research and Development Program contractpharma
August 30, 2019
Phase 3 trial evaluating Rova-T as a first-line therapy for SCLC demonstrated no survival benefit for patients.
AbbVie receives FDA approval for RINVOQ biospectrumasia
August 20, 2019
RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis